Clearbridge Investments LLC Sells 8,194 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Clearbridge Investments LLC trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 409,711 shares of the company's stock after selling 8,194 shares during the quarter. Clearbridge Investments LLC owned approximately 1.32% of Medpace worth $136,118,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MEDP. R Squared Ltd acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace during the 4th quarter valued at $31,000. Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, True Wealth Design LLC raised its position in shares of Medpace by 16,800.0% in the third quarter. True Wealth Design LLC now owns 169 shares of the company's stock valued at $56,000 after purchasing an additional 168 shares during the period. Institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MEDP. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, Leerink Partnrs raised Medpace to a "hold" rating in a report on Monday, March 24th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Medpace has an average rating of "Hold" and an average price target of $376.30.

Remove Ads

Medpace Stock Down 5.6 %

Shares of NASDAQ:MEDP traded down $17.00 during trading on Friday, reaching $287.11. 833,195 shares of the company traded hands, compared to its average volume of 307,369. The firm has a market capitalization of $8.75 billion, a PE ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a 52 week low of $282.42 and a 52 week high of $459.77. The company's 50 day moving average is $331.56 and its two-hundred day moving average is $337.60.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.